Stock Market Reviews

LYEL (Lyell Immunopharma, Inc.) News

Get the latest news, insights, and market updates on LYEL (Lyell Immunopharma, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• The Zacks Analyst Blog Mineralys, Lyell, Insmed and Nektar
  Mineralys Therapeutics leads a biotech surge, with four drug stocks up over 50% in 2025 and catalysts lining up for more upside in 2026.
  Dec 26, 2025 - $LYEL
• 4 Drug, Biotech Stocks Rising More Than 50% in 2025 With Room to Grow
  MLYS, LYEL, NKTR and INSM rise more than 50% in 2025 as clinical wins, FDA approvals and M&A deals revive sector momentum heading into 2026.
  Dec 24, 2025 - $LYEL
• Institutional investors are Lyell Immunopharma, Inc.'s (NASDAQ:LYEL) biggest bettors and were rewarded after last week's US$72m market cap gain
  Key Insights Given the large stake in the stock by institutions, Lyell Immunopharma's stock price might be vulnerable...
  Dec 17, 2025 - $LYEL
• Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the 67th ASH Annual Meeting and Exposition
  93% overall response and 76% complete response rates with median progression-free survival of 18 months in patients with large B-cell lymphoma in the 3L+ setting83% overall response and 61% complete response rates in cohort comprised predominantly of patients with primary refractory large B-cell lymphoma in the 2L settingManageable safety profile appropriate for outpatient administration; no high-grade CRS and ≤ 5% of patients with Grade ≥ 3 ICANS following dexamethasone prophylaxisLyell managem
  Dec 7, 2025 - $LYEL
• Lyell Immunopharma: Q3 Earnings Snapshot
  SOUTH SAN FRANCISCO, Calif. AP) — Lyell Immunopharma Inc. LYEL) on Wednesday reported a loss of $38.8 million in its third quarter.
  Nov 12, 2025 - $LYEL
• Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2025
  Acquired exclusive global rights to LYL273, a novel GCC-targeted CAR T-cell product candidate that has demonstrated a 67% overall response rate, an 83% disease control rate and a manageable safety profile at the highest dose level studied to date in patients with refractory metastatic colorectal cancer in an ongoing U.S. Phase 1 clinical trialReceived RMAT designation from the U.S. FDA for ronde-cel for the treatment of patients with relapsed or refractory LBCL receiving treatment in the second-
  Nov 12, 2025 - $LYEL
• Metagenomi, Ovid CEOs step aside; Cogent soars on ‘unprecedented’ stomach cancer data
  Metagenomi is laying of 25% of its staff while switching up leadership. Elsewhere, Ovid announced a CEO succession plan and Cogent Biosciences and Galecto saw their shares skyrocket.
  Nov 12, 2025 - $LYEL
• Lyell acquires worldwide rights from ICT to CAR T-cell therapy
  US Phase I clinical trial data reveal dose-dependent activity of LYL273 in 12 patients.
  Nov 11, 2025 - $LYEL
• Lyell Immunopharma Acquires Exclusive Global Rights to a Next-Generation CAR T-Cell Product Candidate in Clinical Development for Metastatic Colorectal Cancer
  LYL273 has demonstrated a 67% overall response rate, an 83% disease control rate, and a manageable safety profile at the highest dose level studied to date in patients with refractory metastatic colorectal cancer enrolled in an ongoing U.S. Phase 1 clinical trialLYL273 is a GCC-targeted CAR T-cell product candidate armed with enhancements designed to improve CAR T-cell expansion and cancer cell killingLyell management will host an investor webcast at 8:30 AM ET today SOUTH SAN FRANCISCO, Calif.,
  Nov 10, 2025 - $LYEL
• Lyell Announces Two Oral Presentations from the Phase 1/2 Clinical Trial of Ronde-Cel for the Treatment of Aggressive Large B-Cell Lymphoma at the 67th ASH Annual Meeting and Exposition
  SOUTH SAN FRANCISCO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation CAR T-cell therapies for patients with cancer, today announced that two abstracts highlighting new clinical and translational data from the Phase 1/2 clinical trial of rondecabtagene autoleucel (ronde-cel, also known as LYL314) for the treatment of aggressive large B-cell lymphoma (LBCL) will be presented at the 67th America
  Nov 3, 2025 - $LYEL